[SCHEDULE 13G/A] Vaxcyte, Inc. SEC Filing

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson disclose a 10.1% beneficial stake in Vaxcyte, Inc. The Schedule 13G/A reports combined beneficial ownership of 13,132,825.71 shares of Vaxcyte common stock. FMR LLC is shown with sole voting power over 13,090,519 shares and sole dispositive power over 13,132,825.71 shares; Abigail P. Johnson is reported with sole dispositive power for the same aggregate amount. The filing states that some other persons may have rights to dividends or sale proceeds but no other single person holds more than 5% of the class. An Exhibit 99 agreement is referenced for related identification and classification details.

Positive

• Material ownership disclosed: The filing reports a clear, specific beneficial ownership amount of 13,132,825.71 shares (10.1%).
• Clear voting/dispositive breakdown: FMR LLC reports sole voting power over 13,090,519 shares and sole dispositive power over 13,132,825.71 shares.
• Compliance and certification: The statement includes the required certification that the holdings are in the ordinary course of business and not intended to change control.

Negative

• None.

Insights

Financial Analyst

TL;DR: A single investor group reports a >10% stake, which is material and could influence market attention but is a disclosure, not an action.

The Schedule 13G/A shows FMR LLC and Abigail P. Johnson beneficially own 13,132,825.71 shares, representing 10.1% of Vaxcyte's common stock. The breakdown shows concentrated dispositive authority with FMR LLC holding nearly all sole voting power reported. This is a routine regulatory disclosure that signals a significant passive stake; it does not, on its face, indicate a change in control intent or any transaction. Investors should note the size of the holding relative to the outstanding class as a material ownership disclosure.

Corporate Governance Expert

TL;DR: Ownership concentration exceeds 5%, requiring disclosure; governance influence is possible but no coordinated group or control intent is asserted.

The filing classifies the position under Schedule 13G/A and specifies sole voting and dispositive powers without shared control or group affiliation. The statement includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing control. An Exhibit 99 is referenced for subsidiary/identification details. This documentation satisfies regulatory transparency for a material passive stake.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

VAXCYTE INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

92243G108

(CUSIP Number)

08/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92243G108

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 13,090,519.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 13,132,825.71
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,132,825.71

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.1 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 92243G108

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 13,132,825.71
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,132,825.71

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VAXCYTE INC
(b)	Address of issuer's principal executive offices: 825 INDUSTRIAL ROAD,STE. 300,SAN CARLOS,CA,USA,94070
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 92243G108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 13132825.71
(b)	Percent of class: 10.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 13132825.71
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VAXCYTE INC. No one other person's interest in the COMMON STOCK of VAXCYTE INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	09/05/2025

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	09/05/2025

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many Vaxcyte (PCVX) shares does FMR LLC report owning?

FMR LLC reports beneficial ownership of 13,132,825.71 shares of Vaxcyte common stock, representing 10.1% of the class.

What voting power does FMR LLC hold in Vaxcyte (PCVX)?

FMR LLC reports sole voting power over 13,090,519 shares and sole dispositive power over 13,132,825.71 shares.

Does Abigail P. Johnson have voting power for the reported Vaxcyte stake?

Abigail P. Johnson is reported with 0 sole voting power and 0 shared voting power but with sole dispositive power over 13,132,825.71 shares.

Does this filing indicate an intent to change control of Vaxcyte (PCVX)?

No. The filing includes a certification stating the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.

Is there additional detail about subsidiaries or agreements?

Yes. The filing references Exhibit 99 for a 13d-1(k)(1) agreement and for identification/classification details of relevant subsidiaries.